Login

Omega Therapeutics, Inc. SEC Filings

Filed On Filing
31 Mar 2025 15-12G
25 Mar 2025 EFFECT
21 Mar 2025 POS AM
21 Mar 2025 S-8 POS
20 Mar 2025 25
07 Mar 2025 SCHEDULE 13G/A
24 Feb 2025 8-K: Entry into a Material Definitive Agreement; Notice of Delisting or Failure to Satisfy a Listing Rule

As previously disclosed, on February 10, 2025, Omega Therapeutics, Inc., a Delaware corporation (the “Company” or “Debtor”), filed a voluntary petition for relief under Chapter 11 of Title 11 of the United States Code (the “Bankruptcy Co...

14 Feb 2025 8-K: Entry into a Material Definitive Agreement; Bankruptcy or Receivership +1 more

The information set forth below in Item 1.03 of this Current Report on Form 8-K (this “Form 8-K”) regarding the DIP Facility is incorporated herein by reference. All capitalized terms not otherwise defined in this Item 1.01 shall have th...

05 Feb 2025 144
05 Feb 2025 SCHEDULE 13D/A
04 Feb 2025 Form 3: Varsalone Jeffrey T, Director

No securities owned

03 Feb 2025 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +4 more

On February 3, 2025, Omega Therapeutics, Inc. (the “Company”) entered into a Restructuring Support Agreement (together with all exhibits and schedules thereto, the “RSA”) with Pioneering Medicines 08-B, Inc. (the “Supporting Party”), an ...

28 Jan 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

17 Jan 2025 8-K: Triggering Events That Accelerate a Financial Obligation

Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.

10 Jan 2025 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

31 Dec 2024 SCHEDULE 13D/A
31 Dec 2024 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

On December 30, 2024, Michelle C. Werner notified Omega Therapeutics, Inc. (the “Company”) of her resignation as a member of the Board of Directors of the Company (the “Board”) and the Nominating and Corporate Governance Committee of the...

06 Dec 2024 8-K: Departure/Election of Directors or Officers; Compensation

On December 3, 2024 (the “Effective Date”), the Board of Directors (the “Board”) of Omega Therapeutics, Inc. (the “Company”) elected Ravi Mehrotra, Ph.D. as a Class II director of the Company, effective immediately. On the Effective Date...

05 Dec 2024 Form 4: Mehrotra Ravi, Director

Granted 50,000 Stock Option (Right to Buy)

05 Dec 2024 Form 3: Mehrotra Ravi, Director

No securities owned

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support